MRNS MARINUS PHARMACEUTICALS INC

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference

RADNOR, Pa.--(BUSINESS WIRE)--

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference.

The fireside chat will take place on Wednesday, May 15 beginning at 1:35 p.m. Eastern Time.

A link to the event can be accessed on the Investors and Media page of Marinus’ website at . A replay of the webcast will be available approximately two hours after the completion of the event and will be archived for up to 90 days.

About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescription medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in 2022 and continues to invest in the potential of ganaxolone in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information about Marinus visit .

EN
02/05/2024

Underlying

MRNSMARINUS PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MARINUS PHARMACEUTICALS INC

 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sc...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in the global Phase 3 TrustTSC trial evaluating oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex (TSC) in children and adults. “We are pleased to announce we have completed enrollment in our pivotal Phase 3 trial in tuberous sclerosis complex,” said Alex Aimetti, Ph.D., Chief Scientific Officer at Marinus Pharmaceuticals. “The TrustTSC study enrolled hi...

16h / 21m 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Provides Business Update and Reports First Qua...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2024. “Our unwavering commitment is to develop innovative treatment options for individuals with seizure disorders,” said Scott Braunstein, M.D., Chairman and Chief Executive Officer of Marinus. “With continued commercial success in CDD and a significant unmet need in drug-resistant epilepsies, we believe there is a robust market opportun...

May 8, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Glo...

RADNOR, Pa.--(BUSINESS WIRE)-- (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference. The fireside chat will take place on Wednesday, May 15 beginning at 1:35 p.m. Eastern Time. A link to the event can be accessed on the Investors and Media page of Marinus’ website at . A replay of the webcast will be available approximately two hours af...

May 2, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals to Provide Business Update and Report First Qu...

RADNOR, Pa.--(BUSINESS WIRE)-- , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. The press release will be available on Marinus’ investor relations website at . About Marinus Pharmaceuticals Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company first introduced FDA-approved prescripti...

May 1, 2024 1 EN
 PRESS RELEASE
Free
MRNS MARINUS PHARMAC...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listi...

RADNOR, Pa.--(BUSINESS WIRE)-- . (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of its common stock (the “Common Stock”) as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). These stock option grants have an exerci...

April 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch